Pre-made Natalizumab benchmark antibody ( Whole mAb, anti-ITGA4 therapeutic antibody, Anti-CD49D/IA4 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-367
Pre-Made Natalizumab biosimilar, Whole mAb, Anti-ITGA4 Antibody: Anti-CD49D/IA4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in multiple sclerosis.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Natalizumab biosimilar, Whole mAb, Anti-ITGA4 Antibody: Anti-CD49D/IA4 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||4irz:HL|
|95-98% SI Structure||None|
|Companies||Biogen;Biogen Idec;Elan Corporation;Perrigo|
|Conditions Approved||Crohn's disease;Multiple sclerosis|
|Conditions Active||Epilepsy;Graft-versus-host disease;Stroke|
|Conditions Discontinued||Multiple myeloma;Rheumatoid arthritis|